Claro Advisors LLC Grows Position in CVS Health Co. (NYSE:CVS)

Claro Advisors LLC raised its position in CVS Health Co. (NYSE:CVSFree Report) by 27.1% during the third quarter, HoldingsChannel.com reports. The firm owned 12,024 shares of the pharmacy operator’s stock after buying an additional 2,563 shares during the quarter. Claro Advisors LLC’s holdings in CVS Health were worth $756,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of CVS. Resurgent Financial Advisors LLC raised its holdings in shares of CVS Health by 45.3% during the 1st quarter. Resurgent Financial Advisors LLC now owns 4,339 shares of the pharmacy operator’s stock valued at $346,000 after buying an additional 1,352 shares during the period. Davis R M Inc. raised its holdings in shares of CVS Health by 8.7% during the 1st quarter. Davis R M Inc. now owns 3,010 shares of the pharmacy operator’s stock valued at $240,000 after buying an additional 242 shares during the period. Bahl & Gaynor Inc. raised its holdings in shares of CVS Health by 11.9% during the 1st quarter. Bahl & Gaynor Inc. now owns 15,833 shares of the pharmacy operator’s stock valued at $1,263,000 after buying an additional 1,680 shares during the period. Rockport Wealth LLC purchased a new stake in shares of CVS Health during the 1st quarter valued at about $242,000. Finally, O Shaughnessy Asset Management LLC raised its holdings in shares of CVS Health by 34.9% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 86,556 shares of the pharmacy operator’s stock valued at $6,904,000 after buying an additional 22,400 shares during the period. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Trading Down 3.4 %

NYSE:CVS opened at $53.19 on Monday. CVS Health Co. has a 12-month low of $52.71 and a 12-month high of $83.25. The firm has a market capitalization of $66.93 billion, a P/E ratio of 13.50, a P/E/G ratio of 0.92 and a beta of 0.55. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The business has a 50 day simple moving average of $59.23 and a 200 day simple moving average of $58.60.

CVS Health (NYSE:CVSGet Free Report) last released its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The business had revenue of $95.43 billion during the quarter, compared to analyst estimates of $92.72 billion. During the same quarter in the previous year, the firm posted $2.21 EPS. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. Equities research analysts predict that CVS Health Co. will post 5.48 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Monday, October 21st were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 5.00%. The ex-dividend date was Monday, October 21st. CVS Health’s payout ratio is currently 67.51%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Truist Financial raised their target price on CVS Health from $66.00 to $76.00 and gave the company a “buy” rating in a report on Friday, October 11th. Deutsche Bank Aktiengesellschaft dropped their price objective on CVS Health from $64.00 to $63.00 and set a “hold” rating on the stock in a report on Friday, August 9th. UBS Group lifted their price objective on CVS Health from $60.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. TD Cowen upgraded CVS Health from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $59.00 to $85.00 in a report on Friday, October 4th. Finally, Barclays dropped their price objective on CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $72.44.

Get Our Latest Research Report on CVS Health

CVS Health Company Profile

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Featured Stories

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSFree Report).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.